IONIS PHARMACEUTICALS INC Collaboration Agreements

Collaboration and License Agreement by and between the Registrant and Novartis Pharma AG dated as of August 2, 2023. Portions of this exhibit have been omitted because they are... (Filed With SEC on November 2, 2023)

Letter Agreement dated June 29, 2023 in reference to the Collaboration and License Agreement dated December 6, 2021 by and between Akcea Therapeutics, Inc. and AstraZeneca AB.... (Filed With SEC on August 9, 2023)

Amendment No. 3 dated April 27, 2023 to the Collaboration and License Agreement by and between the Registrant and BicycleTx Limited dated July 9, 2021. Portions of this exhibit... (Filed With SEC on August 9, 2023)

Amendment No. 2 dated July 28, 2022 to the Collaboration and License Agreement by and between the Registrant and BicycleTx Limited dated July 9, 2021. Portions of this exhibit... (Filed With SEC on November 9, 2022)

First Amendment dated July 8, 2022 to Factor B Development, Collaboration, Option and License Agreement by and between the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La... (Filed With SEC on August 9, 2022)

Amendment No. 1 dated December 17, 2021 to the Collaboration and License Agreement by and between the Registrant and BicycleTX Limited dated July 9, 2021. Portions of this exhibit... (Filed With SEC on February 25, 2022)

COLLABORATION AND LICENSE AGREEMENT between BICYCLETX LIMITED and IONIS PHARMACEUTICALS, INC. Dated as of July 9, 2021 (Filed With SEC on November 3, 2021)

Amended and Restated Neurology Drug Discovery and Development Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc., And Biogen MA Inc. Dated July 12,... (Filed With SEC on November 3, 2021)

Side Letter dated December 31, 2020 to the New Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between the Registrant and... (Filed With SEC on February 24, 2021)

Amendment No. 3 dated December 17, 2020 to the Strategic Collaboration Agreement by and between the Registrant and AstraZeneca AB dated July 31, 2015. Portions of this exhibit... (Filed With SEC on February 24, 2021)

First Amendment to Research Collaboration, Option and License Agreement between the Registrant and Janssen Biotech Inc. dated December 21, 2016. Portions of this exhibit have been... (Filed With SEC on February 24, 2021)

Research Collaboration, Option and License Agreement between the Registrant and Janssen Biotech Inc. dated December 22, 2014. Portions of this exhibit have been omitted because... (Filed With SEC on February 24, 2021)

Amendment No. 2 to the Strategic Collaboration Agreement by and between the Registrant and AstraZeneca AB dated July 31, 2015 (portions of the exhibit have been omitted because... (Filed With SEC on August 5, 2020)

Side Letter dated June 11, 2020 to the Second Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between... (Filed With SEC on August 5, 2020)

Amendment No. 1 to Second Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between the Registrant and... (Filed With SEC on August 8, 2019)

Factor B Development Collaboration, Option and License Agreement by and between the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated October 9, 2018.... (Filed With SEC on March 1, 2019)

Second Amendment to Research Collaboration, Option and License Agreement of December 22, 2014, by and between Ionis Pharmaceuticals, Inc. and Janssen Biotech Inc. Portions of this... (Filed With SEC on November 6, 2018)

Development, Commercialization, Collaboration, and License Agreement, dated as of March 14, 2018, by and between Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc (Filed With SEC on May 7, 2018)

Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma AG (Filed With SEC on May 9, 2017)

SECOND AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 5, 2015)

Research Collaboration, Option and License Agreement Between Isis Pharmaceuticals, Inc. And Janssen Biotech Inc. (Filed With SEC on March 2, 2015)

Amendment to Amended and Restated Collaboration and License Agreement relating to [***] (Filed With SEC on November 7, 2014)

Amended and Restated Collaboration and License Agreement (Filed With SEC on November 7, 2014)

NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC MA INC. (Filed With SEC on February 28, 2013)

COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND ASTRAZENECA AB (Filed With SEC on February 28, 2013)

AMENDMENT NUMBER ONE TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on August 9, 2010)

COLLABORATION AND LICENSE AGREEMENT between REGULUS THERAPEUTICS INC. And SANOFI-AVENTIS (Filed With SEC on August 9, 2010)

AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 12, 2008)

SECONDAMENDED AND RESTATED COLLABORATION AGREEMENT BETWEEN ELI LILLYAND COMPANY AND ISISPHARMACEUTICALS, INC. August 5,2005 (Filed With SEC on November 9, 2005)